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Objective: We hypothesized that ex vivo hyperbar ic  transfect ion of 
ant isense ol igodeoxynucleotides for blockade of intercel lu lar  adhesion 
molecu le- l ,  an important  mediator  of cell adhesion and T-cell co- 
st imulat ion, would reduce chronic graft vascular  disease in cardiac 
al iografts. Methods: PVG hearts underwent ex vivo transfect ion with 
antisense, reverse ant isense intercel lu lar  adhesion molecule-1 oligode- 
oxynucleotide (80 /~mol/L), or saline solution at 3 atm pressure for 45 
minutes at 4 ° C and were t ransp lanted heterotopical ly into ACI recipi-  
ents with or without t reatment  with intercel lu lar  adhesion molecule-1 
(1A29) or leukocyte function associated antigen-1 (WT.1) monoclonal  
antibodies. Transfect ion efficiency was confirmed with f luorescein iso- 
th iocyanate- labeled ol igodeoxynucleotides and f luorescent microscopy. 
Efficacy of int racel lu lar  adhesion molecule-1 blockade was assessed 
with the use of immunohistochemistry.  Graft  reperfusion injury was 
evaluated at 6 to 24 hours by neutrophi l  inf i l trat ion (myeloperoxidase 
[MPO]) ,  cardiac edema (%wt/wt), and histologic injury (percent con- 
tract ion band necrosis).  Grafts  from recipients treated with cyclospor- 
ine A (5 mg/kg per day, days 0 to 9) were scored for chronic graft 
vascular  disease on postoperat ive day 90 ranging from 0 (no inwflve- 
ment) to 4 (>50% vascular  occlusion). Results: Transfect ion was highly 
efficient (f luorescein isoth iocyanate- labeled ol igodeoxynucleotides in 
48% +_. 5% of total myocardia l  nuclei) and effective at blocking intracel-  
lu lar  adhesion molecule-1 expression (positive area in al lografts taken 
on postoperat ive day 3 was reduced from 100% + 0% to 52% - 14%, n = 
4). Blockade with ant isense ol igodeoxynucleotides versus monoclonal 
ant ibodies was less effective at preventing reperfusion injury while more 
effective at reducing chronic graft vascular disease (score 0.98 -+ 0.48, 
p < 0.05). Reverse ant isense ol igodeoxynucleotides and vector control 
(antisense ol igodeoxynucleotide infusion without pressure)  groups 
failed to demonstrate this beneficial effect. Conclusion: Hyperbar ic  
transfection of ant isense ol igodeoxynucleotides proved highly efficient, 
effective at blockade of int race l lu lar  adhesion molecu le- l ,  and demon- 
strated a sequence-specific reduction in chronic graft vascular  disease. 
This highly targeted al terat ion of donor organ immunogenicity may have 
an important  future role in cl inical immunosuppress ive strategies. 
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C hronic cardiac allografl rejection is a process that is thought to be due to alloantigen-dependent 
and -independent events ~ and results in a diffuse 
coronary vascular narrowing termed chronic graft 
vascular disease (CGVD). Current immunosuppres- 
sants, although effective at controlling acute alloim- 
mune responses, have not altered the devastating 
impact of CGVD on long-term graft survival. Ex 
vivo somatic gene therapy has been proposed as a 
novel, highly targeted strategy of genetically manip- 
ulating donor allografts to prevent CGVD. Unlike 
genetic engineering applications uch as cloning, 
somatic gene therapy has yet to prove clinically 
useful, primarily because of consistently poor trans- 
fection efficiency. 
We 2' ~ have used hydrostatic pressure as a novel, 
technically simple, nontoxic vector for nuclear de- 
livery of phosphorothioate oligodeoxynucleotides 
(ODN) to a variety of tissues. The consistently high 
transfection elticiency of this method in cardiac 
tissues raises the intriguing possibility of using anti- 
sense technology for cardiac allograft immunosup- 
pression. In the present studies, phosphorothioate 
antisense oligonucleotides (AS ODN) that bind 
specifically to the target messenger ribonucleic acid 
(mRNA) of intercellular adhesion molecule-1 
(ICAM-1) were delivered to cardiac allografts ex 
vivo by means of this hyperbaric vector. ICAM-1 
was chosen as the antisense target because its ex- 
pression is solely transcriptionally regulated 4 and 
low at baseline in myocardium. 5 Furthermore, the 
central role that ICAM-1 maintains in allograft 
pathophysiology makes it an ideal immunosupprcs- 
sive target. 
Specific blockade of this molecule interrupts the 
positivc feedback cascade of [CAM-1 with its ligand, 
leukocyte function associated antigen-1 (LFA-1), 
and results in reduced neutrophil-mediated reperfu- 
sion injury 6 and donor-specific allograft toler- 
ance.7,8 It has been shown that early nonspecific 
inflammation from reperfusion injury up-regulates 
graft immunogenicity and therefore increases the 
rates of acute 9 and chronic rejection, m In addition 
to indirectly promoting CGVD via reperfusion in- 
jury, clinical 11 and experimental 12 models have re- 
vealed a second, later phase of ICAM-I up-regula- 
tion that coincides with the histologic onset of 
vasculopathy, suggesting a more direct pathogenic 
role of ICAM-I  in development of CGVD. 
Regardless of the exact mechanism of effect, we 
hypothesized that the ex vivo blockade of ICAM-1 
in donor grafts would reduce the severity of vascu- 
lopathy in a rodent cardiac allograft model of 
CGVD. 
Methods 
Drugs and agents. The sequence chosen for synthesis 
of the rat AS ODN (Keystone Laboratories, Inc., Menlo 
Park, Calif.) was modified from a previously reported s 
mouse AS ICAM-I ODN using information obtained 
from GenBank regarding the differences of rat 13 and 
mouse 14 ICAM-1 mRNA at the homologous 3' untrans- 
lated target region: 
Mouse ICAM-1 mRNA (base No. 1755-74): 5'-ATG GTG 
GCC TGG GGG ATG CA-3' 
AS mRNA (IP3082): 3'-TAC CAC CGG ACC CCC TAC 
GT-5' 
Rat ICAM-1 mRNA (base No. 1768-87): 5'-ACA GTG 
GCC TGG GGA TGC A-3' 
AS mRNA (used in our study): 3'-TGT CAC CGG ACC 
CCT ACG T-5' 
(bold type represents bases that differ between mouse and rat 
ICAM-1 mRNA and AS at this region). 
For studies to address the efficiency of transfection, 
ODN with a scrambled sequence was synthesized and 
labeled on the 5' and 3' ends with fluorescein isothiocya- 
nate (F1TC). For investigation of the true antisensc 
mechanism of AS ODN, control reverse antisense (RAS) 
sequences were synthesized. LFA-1 and ICAM-1 mono- 
clonal antibodies (MAb) were purified from the ascites of 
mice injected with hybridomas (WT.1 and 1A29, gift of M. 
Miyasaka, Osaka, Japan) and administered via the dorsal 
penile vein at 1.5 mg/kg per day from postoperative day l) 
to day 6. This dose was confirmed to promote full 
saturation of their respective ligands on peripheral blood 
leukocytes 24 hours after administration by flow cytomet- 
ric analysis. Cyclosporine A (INN: ciclosporin) was dis- 
solved in olive oil (10 mg/ml) and administered via garage 
at a dose of 5 mg/kg for 10 days after the operation to 
prevent acute rejection and allow for the development of
CGVD in all groups. 
Animals. Adult male (8 to 10 weeks old, 230 to 270 gin) 
PVG (RTlc) and ACI (RTla) rats were obtained fiom 
Harlan Sprague Dawley, Indianapolis, Indiana. All ani- 
mals were maintained in the animal care facilities of the 
Department of Cardiothoracic Surgery, Stanford Univer- 
sity Medical Center, Stanford, California. Their environ- 
ment was maintained at 21 ° ± 2 ° C with a time-regulated 
light period from 7:00 AM to 7:00 PM. Rats were provided 
water and dry food ad libitum. Periodic serologic analysis 
of room sentinel animals howed that all rats were free of 
acute viral infection. All animals received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy 
of Sciences and published by the National Institutes ol 
Health (NIH Publication No. 86-23, revised 1985). 
Heart transplantation. Both donor and recipient rats 
were anesthetized with methoxyflurane (inhalational) and 
sodium pentobarbital (50 mg/kg intraperitoneally). Hearts 
were procured and either underwent transfection or mock 
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Table I. Study groups 
Group Treatment No. Pwpose 
Experimental Ex vivo AS ODN 
ODN control Ex vivo RAS ODN 
Vector control Ex vivo AS ODN 
without pressure 
Negative control None 
Positive control No. 1 ICAM-1 MAb 
(given to recipient) 
Positive control No. 2 LFA-1 MAb 
(given to recipient) 
25 
6 
6 
10 
25 
25 
To assess biologic effects of AS 
ODN transfection on CGVD 
To control for non-AS (e.g., 
aptamer) biologic effects of ODN 
To verily the need for transfection 
to have biologic effects 
For CGVD comparison 
To compare ffects of ICAM-1 
blockade with AS ODN vs MAb 
(gold standard) 
To control for endothelial ctivating 
effects of ICAM-1 MAb 
transfection as described below. After incubation, hearts 
were grafted heterotopically into the abdomen of allo- 
genie recipients by means of a modification of the meth- 
ods described by Ono and Lindsay. 14a Immediately after 
reperfusion and daily thereafter, grafts were assessed for 
successful return of rhythmic cardiac contractions on a 
scale ranging from 0 (no contractions) to 4 (vigorous 
contractions). Primary failure was defined in grafts that 
did not achieve an immediate palpation score greater than 
2. After an initial period of successful function, hearts 
were considered acutely rejected when palpation scores 
were less than 1. Grafts with either of these diagnoses 
were excluded from further analysis. 
In vivo transfection efficiency. Alter donor rat thora- 
cotomy, ice cold Stanford cardioplegic solution was ap- 
plied to the heart opically and infused into the aortic root 
proximal to an aortic crossclamp for coronary perfusion. 
Alter complete cardioplegic arrest, the coronary arteries 
were perfused with FITC-tagged scrambled ODN solution 
(0.5 ml of 80 /Lmol/L ODN in phosphate-buffered saline 
solution at 1 ml/min). The heart was then cxplanted, 
placed into a well of ODN solution in an ice bath at 4 ° C, 
and pressurized to 3 arm in a custom-designed pressure 
vessct for 45 minutes. Donor hearts treated with the above 
protocol without the use of pressure served as the control 
group. After 24 hours' reperfusion in the recipient, grafts 
were procured, flushed with ice-cold phosphate-buffered 
saline solution, and immediately snap frozen in OCT 
embedding compound in liquid nitrogen. After equilibra- 
tion to -20 ° C, 6/ ,m sections were taken perpendicular to
the long axis of the heart from the superior, midportion, 
and interior portions of the grafts. Hoechst dye was used 
to facilitate identification of total nuclei under fluorescent 
microscopy, and transfection efficiency was assessed by 
determining the percentage of myocardial nuclear local- 
ization of fluorescence in 5 random high-power (×100) 
fields chosen from each of three graft regions (superior, 
midportion, and inferior) for a total of 15 high-power 
fields per graft. 
Verification of transfection efficacy. After confirmation 
of transfection efficiency, we then verified that the delivery 
of AS ODN by means of the hyperbaric method would 
successfully prevent ICAM-1 up-regulation i the PVG to 
ACI model of acute rejection. On the basis of pilot studies 
of tCAM-I protein expression analyzed in control PVG 
allografts by Western blot and immunohistochemistry, 
postoperative day 3 was chosen as the time point most 
appropriate for comparison with AS ODN transfected 
grafts. PVG grafts were transfected with AS ICAM-1 
ODN or RAS ODN and heterotopically transplanted into 
the abdomen of untreated ACI recipients. Hearts were 
procured on postoperative day 3 for immunohistochemi- 
cal assessment of ICAM-1, CD4, CD8, macrophage, and 
major histocompatibility complex (MHC) classes i and II 
using the method outlined in the Histostain SP kit (Zymed 
Laboratories, South San Francisco, Calif.). In brief, 6/ ,m 
sections were air dried at room temperatnre and fixed in 
acetone at 20 ° C. Sections were rehydrated in 1% bovine 
albumin-phosphate buffered saline solution and then 
incubated with the one of the following primary antibod- 
ies (from Serotec, Westbury, N.Y.): 1A29 (ICAM-I), 
W3/25 (CD4), MRC OX-8 (CD8), EDI and ED2 (mac- 
rophage), 156 and 280 (MHC class I), and 46 (MHC class 
II). This was followed by incubation with a biotinylated 
goat antimouse immunoglobulin G (Zymed Laboratories, 
South San Francisco, Calif.). The avidin-biotin complex 
was applied and diaminobenzidine tetrahydrochloride was 
used as the chromogen. The substitution of 1% bovine 
albumin-phosphate buffered saline solution for the pri- 
mary antibody served as the negative (reagent) control. 
Rat cervical ymph nodes served as the ICAM-I  positive 
control. Sections from transfected and control grafts were 
semiquantitatively scored (0 to 3+) for antigen staining 
intensity by a pathologist blinded as to experimental 
group. Computer-assisted image analysis (C-Imaging Sys- 
tems, Cranberry Twp., N.J.) was used to measure the total 
graft cross-sectional area positive for ICAM-1 to provide 
a quantitative assessment of the AS effect. 
Assessment of biologic effects of ex vivo AS ICAM-1 
ODN. The biologic effects of ex vivo AS ODN transfec- 
tion (experimental group, n = 25) were compared with 
five additional control groups as shown in Table l: an 
ODN control (n = 6), a vector control (n = 6), a negative 
control (n = 10), and two positive control groups. Rats in 
the positive control groups received untransfected grafts 
and were treated with a single injection of ICAM-I MAb 
(positive control 1, n = 25) or LFA-I MAb (positive 
control 2, n = 25) 1.5 mg/kg intravenously just before graft 
reperfusion. After successful return of heart contractions, 
grafts were either procured at 6, 12, and 24 hours to assess 
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Fig. 1. After a short postoperative course of cyclosporine A, ACI recipients were put to death on 
postoperative day 90 so that CGVD in the heterotopic PVG allografts could be assessed. Although grafts 
from both groups displayed the classic histologic findings of concentric neointimal hyperplasia inside the 
internal elastic lamina (arrow), negative control allografts were found to have a significantly greater number 
of vessels coring greater than 3 as illustrated in these representative photomicrographs. (Hematoxylin- 
eosin, original magnifications 200x.) 
reperfusion injury or the recipients were treated with a 
10-day course of cyclosporine A 5 mg/kg per day via 
gastric gavage to promote long-term graft survival and 
allow for the development of CGVD. Studies of reperfu- 
sion injury analyzed three parameters of myocardial in- 
jury: (1) cardiac edema using percent wet weight assay 
(%wt/wt)--heart weighed before and aftcr drying in an 
oven at 100°C for 24 hours; (2) neutrophil infiltration 
assessed by MPO enzyme activity--total protein isolated 
from frozen tissuc and assayed for change in absorbance 
at 470 nm at 1 minute after addition of guaiacol and 
peroxide, and (3) histologic injury as determined by the 
presence of contraction band necrosis (%CBN)--after 
initial review with a pathologist, the percentage cross- 
sectional area of a trichrome-stained section involved with 
contraction band ecrosis was quantitatively determined 
by means of computer-assisted image analysis (C-imaging 
systems, Cranbcrry Twp., N.J.). 
For CGVD analysis, grafts wcrc removed on postoper- 
ative day 90 for sectioning after fixation in buffered 
formalin for 24 hours. Thin sections of paraffin-embedded 
samples stained with hematoxylin-eosin a d Evans-van 
Gieson stains were exanrined by a pathologist (M.B.) 
blinded as to experimental group and assigned a CGVD 
score. This score was the mean score for all the individual 
vessels in a section and therefore represented the fact that 
normal and occluded vessels were often found in the same 
sections (i.e., displayed high standard eviations). Individ- 
ual vessels were subjected to a five-point grading scale 
from 0 to 4 (0 for no involvement, 1 for partial intimal 
involvement, 2 for concentric intimal thickening, 3 for 
more severe concentric involvement up to 50% luminal 
narrowing, and 4 for > 50% up to complete occlusion) 
(Fig. 1). 
Immunohistochemical studies. PVG cardiac grafts 
were transfccted widl AS ICAM-10DN or mock trans- 
feeted with saline solution for 45 minutes at 4°C and 
grafted into ACI recipients treated with cyclosporin A 5 
mg/kg via gavage on postoperative days 0 to 9. Grafts (n 
3 each time point) were then procured at 6, 12, and 24 
hours and on postoperative days 30, 60, and 90. Grafts 
were divided so that adjacent sections were snap frozen in 
OCT embedding compound (Miles, Elkhart, Ind.) for 
immunohistochemical staining using the Histostain SP kit 
(Zymed Laboratories, South San Francisco, Calif.) and 
fixed in formalin for Evans-van Gieson staining to assess 
CGVD. lmmunohistochcmistry sections were scored (0 to 
3+) in terms of both overall and specifically perivascular 
staining intensity for ICAM-1, CD4, CD8, macrophage, 
and MHC classes I and II by a pathologist blinded as to 
the experimental group. The immunohistochemistry and 
Evans~an Gieson findings of each artery and arteriole of 
the grafts were compared to identify any correlation 
between positive perivascular ICAM-I staining (score > 
1) and underlying vasculopathy (CGVD scorc > 2). 
Statistical analysis. Transfection efficicncy data (per- 
cent nuclear fluorescence) was compared between groups 
using the Mann-Whitney U test. The parameters of 
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Fig. 2. Hyperbaric transfection lcd to highly efficient myocyte delivery of ODN as illustrated by thc large 
number of total myocardial nuclei (shown on the Hoechst dye stain, B), which demonstrate nuclear 
localization of fluorescence (shown under thc fluorescent fil er, A). Intracoronary infusion of FITC-ODN 
without application of pressure did not lead to appreciable transfection, as indicated by the failure of 
Hoechst @c-positive nuclei (D) to show nuclear localization of fluorescence (C). (All original magnifica- 
tions 200x.) 
reperfusion i jury, MPO and %wt/wt, wcre compared by 
means of analysis of variance with a post hoc t test. Given 
the consistently unequal standard eviations noted in the 
mean areas of percent contraction band necrosis and 
percent ICAM-1 staining between groups, the Welch t test 
was required for comparison of these data. CGVD scores 
were compared between groups by means of the Mann- 
Whitney U test. An association between positive perivas- 
cular ICAM-1 staining of any given artery on immunohis- 
tochemical analysis (defined as a score > 1) and 
underlying vasculopathy of that vessel (defined as CGVD 
score > 2) was investigated by means of the Fisher exact 
test. 
Results 
Transfectinn efficiency. Hyperbaric transfection 
was highly efficient but non-uniform, with some but 
not all areas showing dense nuclear fluorescence 
(sections with up to 90% of nuclei) after 24 hours of 
reperfusion. Low-power fluorescent microscopic ex- 
amination of these areas revealed the highly effi- 
cient, homogeneous nature of fluorescent nuclear 
localization of F ITC-ODN relative to the total 
nuclei as shown by examining the same section 
under the Hoechst filter (Fig. 2, A and B). Ran- 
domly chosen high-power fields documented that a 
mean of 48% _+ 5% (it = 5) of total nuclei per graft 
were successfully transfected as indicated by this 
nuclear localization of FITC. 
Antisense efficacy. On postoperative day 3, un- 
transfected control cardiac grafts undergoing early 
rejection in untreated recipients demonstrated dif- 
fuse dark red ICAM-1 immunohistochemieal stain- 
ing. Ex vivo AS ODN transfection significantly, 
although inhomogeneously, affected ICAM-1 ex- 
pression at this time point, as illustrated in the 
representative photomicrograph of Fig. 3. By image 
analysis, ICAM-1 staining was reduced to 53% :- 
t4% of total area in AS ODN transfected grafts 
(p < 0.05 vs 100% _+ 0% in control grafts, Student's 
t test, n = 4). This mean cross-sectional rea was 
strikingly similar to the percentage of myocardium 
that was successfully transfected as demonstrated by 
the above efficiency studies. MHC class I and I1[ 
expression was unchanged in transfected grafts (n - 
4), supporting a sequence-specific effect of the AS 
ODN. 
Effect of AS ODN on reperfusion injury. The 
establishment of a highly efficient transfection 
method with documented efficacy at blocking 
ICAM-1 up-regulation provided a rational basis to 
examine for biologic effects of AS ODN. Total 
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Fig. 3. On postoperative day 3, AS ODN was found to effectively block ICAM-1 expression on myocytes 
and prevent vascular expression (arrow) beyond baseline (A) compared with diffuse expression on both cell 
types at this time point in untransfected grafts (B) as illustrated in these representative high-power (original 
magnification 100×) immunohistochemistry sections. However, low-power (original magnification 20x) 
views reveal AS ODN blockade of ICAM-1 expression was inhomogeneous with some areas demonstrating 
diffuse ICAM-1 expression (C) as seen throughout the graft (D) in untreated controls (original 
magnification 20×). 
ischemic times (from cardioplegic arrest of donor 
heart to return of contractions in the recipient's 
abdomen) ranged from 62 to 75 minutes, but there 
were no statistically significant differences in the 
mean ischemic times between groups by analysis of 
variance (data not shown). A single preoperative 
recipient dose of ICAM-1 MAb, included as a 
positive control, prevented the rise in MPO levels 
seen in negative control, untreated grafts most 
prominently at the early t ime points: 6 hours (0.02 + 
0.02 vs 0.10 + 0.04 U/rag protein, n = 6,p < 0.01 by 
analysis of variance) and 12 hours (0.05 _+ 0.06 vs 
0.11 ± 0.04 U/rag protein, n - 6 ,p  < 0.05) (Fig. 4, 
A). Cardiac edema (%wt/wt) in these grafts from 
recipients treated with ICAM- I  MAb followed a 
similar pattern, with significance reached at 6 hours 
(76.30% ± 1.45% vs 79.77% ± 1.32%, n = 6, p < 
0.01) and 12 hours (77.15% _+ 1.29% vs 79.24% ± 
0.71%, n = 6) of reperfusion and no difference at 24 
hours (76.03% _+ 0.89% vs 76.95% + 0.93%, n = 6, 
p = not significant) (Fig. 4, B). Trends toward a 
significant reduction in contraction band necrosis 
after MAb treatment were noted at 12 hours (10.1 _+ 
1.5 vs 12.0 _+ 1.4, n = 5, p = 0.07) and 24 hours 
(10.8 _+ 1.4 vs 12.8 _+ 1.9, n = 6,p = 0.06) (Fig. 4, C). 
Although somewhat less effective, similar reduc- 
tions of cardiac parameters  of reperfusion injury 
were noted in recipients treated with LFA-1 MAb at 
the 6-hour time point (MPO: 0.03 _+ 0.04 vs 0.10 _+ 
0.04 U/mg protein, n - 6,p < 0.05; %wt/wt: 77.02 + 
2.22 vs 79.77 _+ 1.32, n = 6, p < 0.05; %CBN: 9.1% 
_+ 1.8% vs 11.2% ± 1.8%, n = 6,p  = 0.07) and the 
12-hour time point (MPO: 0.06 ± 0.02 vs 0.11 + 
0.04 U/rag protein, n = 6, p < 0.05; %wt/wt: 75.0% 
+ 1.25% vs 79.24% ± 0.71%, n = 5, p - 0.08; 
%CBN: 10.3% + 1.65% vs 12.0% + 2.62%, n = 5, 
p = 0.06). 
Compared with the positive control groups, ex 
vivo AS ODN transfection was relatively less effec- 
tive at preventing early reperfusion injury, display- 
ing a reduction in parameters  of reperfusion injury 
only at the later t ime points. No difference from 
control was noted at 6 hours and only trends toward 
significance were seen at 12 hours (MPO: 0.07 + 
0.02 vs 0.11 +_ 0.04 U/rag protein, n = 5, p = 0.08; 
%wt/wt: 76.9% + 2.19% vs 79.24% _+_ 0.71%, n = 5, 
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Fig. 4. Biologic effects of AS 1CAM-10DN at 6, 12, and 24 hours were assessed in transfected allografts 
by analyzing for three parameters of reperfusion injury: A, neutrophil infiltration using the myeloperoxide 
assay, B, cardiac edema using the %wt/wt assay, and C, histologic injury using image analysis to quantitate 
the percent otal graft area involved with contraction band necrosis. For control, three groups involving no 
donor or recipient reatment (negative control), recipient ICAM-1 MAb (positive control No. 1), or LFA-1 
MAb (positive control No. 2) treatment were compared with the AS ODN experimental group. 
p = 0.06; %CBN:  9.9 ± 2.23 vs 12.0 + 2.62, n = 5, 
p = 0.20). However, statistical significance was 
achieved in these parameters at 24 hours (MPO:  
0.06 ± 0.02 vs 0.10 ± 0.04 U/mg protein,  n = 6 ,p  = 
0.05; %wt/wt: 76.7 _+ 1.25 vs 78.6 ± 1.46, rz = 6 ,p  < 
0.05; %CBN:  9.4% + 1.03% vs 12.8% ± 1.9%, n - 
6, p < 0.02). There was no statistically significant 
difference between the parameters of reperfusion 
injury compared with perioperative ICAM-1 MAb 
at any time point. 
Effect of AS ODN on CGVD. An initial 10-day 
course of cyclosporine A (5 mg/kg per gavage 
tube) promoted long-term PVG allograft survival 
(i.e., >60 days) in 53 of 75 ACI recipients 
(70.7%). Despite prolonged survival of the vigor- 
ously beating allograft, CGVD reproducibly de- 
velops in control PVG grafts with a mean score of 
1.84 + 0.75 (n = 17) (Table I1). Contrary to 
impressive effects on reperfusion injury, perioper- 
ative MAb administration had minimal benefit 
against chronic allograft vasculopathy. After a 
single perioperative dose of either MAb, CGVD 
scores on postoperative day 90 were reduced to 
1.25 ± 1.01, n 10 (anti-ICAM-1 MAb) and 
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Fig. 5. hnmunohistochemical studies from control (untransfected) PVG allografts between postoperative 
days 30 and 90 demonstrated a return to baseline xpression of all antigens analyzed with thc exception of 
a decreased but persistent perivascular expression of MHC class II, CD4, and macrophage antigens 
(original magnifications 200x). AS 1CAM-10DN transfection did not alter these results (data not shown). 
As illustrated in the accompanying hematoxylin-eosin tains (original magnifications 200×), the persistent 
expression of these antigcns was significantly associated with severe vasculopathy (CGVD score > 2). 
1.58 ± 1.13, n = 10 (anti-LFA MAb), differences 
which did not reach statistical significance com- 
pared with untreated controls. On the other hand, 
ex vivo AS ICAM-1 ODN transfection signifi- 
cantly reduced CGVD to 0.98 ± 0.48, n = 10 (p < 
0.05, Mann-Whitney U test). This protective ffect 
on graft vasculature was eliminated by using an 
otherwise identical transfection protocol with the 
substitution of a control RAS ODN sequence 
(1.73 + 0.98, n = 6) or by merely perfusing graft 
coronary arteries with AS ODN without the ap- 
plication of pressure (1.65 _+ 0.78, n = 6). 
Immunohistoehemical studies. Immunohistochem- 
ical studies were then used to further characterize 
the molecular and cellular immune response in 
transfected versus untransfected PVG hearts in ACI 
recipients. At baseline (e.g., before transplantation), 
PVG hearts demonstrated low expression of 
ICAM-1 and MHC class I and I1 antigens with 
almost no CD4 cells, CD8 cells, or macrophages. 
Twelve hours after reperfusion, no significant effect 
Table II. CGVD in AS  ICAM-l - t reated versus 
control heart grafts 
Grotq) No. CGVD score 
Negative control 17 1.84 + 0.75 
Positive control No. 1 10 1.25 +_ 1.01 
Positive control No. 2 10 1.56 _+ 0.96 
ODN control 6 1.73 _+ 0.98 
Vector control 6 1.65 _+ 0.78 
Experimental group 10 0.98 _+ 0.48* 
*p < 0.05, Mann-Whitney U test. 
of AS ODN transfection versus control was noted 
on ICAM-1 expression on arteries (mean score 0 vs 
0, n = 3), arterioles (1.7 vs 2.0), capillaries (2.5 vs 
2.5), veins (2.3 vs 2.5), or myocytes (0 vs 0). On 
postoperative day 1, however, weak ICAM-I  stain- 
ing was noted on the intercalated isks of myocytes 
in control (mean score 0.8, n = 5) but not treated 
grafts (0, n - 6). 
After a short course of cyclosporine A, control 
grafts showed a dramatic increase in the expression 
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Fig. 6. As shown, these representative immunohistochemistry sections procured on postoperative day 90, 
both AS ODN transfccted (A, original magnification 200×) and control allografts (B, original magnifica- 
tion 200×) also demonstrated a return to baseline levels of ICAM-1 cxpression throughout the graft. 
However, specific analysis of arterial (arrow) expression revealed a significantly increased amount of 
pcrivascular ICAM-1 with an associated ICAM-1 positive infiltrate (arrowhead) in control compared with 
AS ODN transfected grafts. 
of all antigens on postoperative day 30 (Fig. 5). By 
day 90, CD8 and MHC class I and II expression 
returned to baseline with decreased but persistent 
CD4 and macrophage accumulation primarily 
around those arteries and arterioles expressing 
ICAM-1 (Fig. 6). The presence of ICAM-1 around 
any given artery, as seen around 45% of allograft 
arteries (33 of 76 total vessels, n = 17), was signif- 
icantly associated with a CGVD score > 2 (p = 0.02, 
Fisher exact est) and provided for a relative risk of 
vasculopathy of 2.04 (95% confidence interval: 1.1 
to 3.9). 
Overall, ex vivo AS ICAM-10DN transfection 
had little effect on antigen expression in PVG 
allografts. ICAM-1, MHC classes I and II, CD4, 
CD8, and macrophage antigen expression followed 
similar patterns to control on postoperative days 30 
and 60. However, on postoperative day 90, there was 
a significant reduction in the number of arteries with 
positive ICAM-1 perivascular staining (15% vs 45%, 
p < 0.02, Fisher exact test), and there were fewer 
associated macrophage and CD4 infiltrates (Fig. 6). 
Those vessels staining positive for perivascular 
ICAM-1 despite x vivo AS ODN transfection were 
at an increased relative risk of CGVD (2.63, 95% 
confidence interval: t.1 to 6.3). 
Discussion 
ICAM-I, an adhesion molecule induced on myo- 
cytes and a wide variety of other cell types after 
cytokine stimulation, mediates major events in host 
inflammatory and immune responses. 4 Ex vivo AS 
ODN blockade of ICAM-1 provides for a more 
graft-specific, yet equally potent antiinflammatory 
and immunosuppressive strategy that avoids the 
infectious risk inherent in recipient ICAM-1 block- 
ade using systemic MAb. In this rodent heterotopic 
transplant model, AS ODN transfection of donor 
cardiac grafts resulted in a reduction of postopera- 
tive ICAM-1 up-regulation and a significant block- 
ade of CGVD compared with untransfected control 
grafts. To our knowledge, no study to date has 
demonstrated a biologic effect of gene therapy on 
the development of CGVD. 
Clinical and experimental studies clearly point to 
an important role for ICAM-1 on the pathogenesis 
of CGVD. By promoting increased reperfusion in- 
jury, early (<24 hours) ICAM-1 up-regulation i di- 
rectly plays a role in the initiation of the vascular 
"response to injury" phenomenon thought respon- 
sible for neointimal hyperplasia of CGVD. In addi- 
tion, the correlation of late (>30 days) up-regula- 
tion of perivascular ICAM-1 expression with 
development of CGVD in this and other mod- 
els,l. 12, 15 suggests a more direct role for this mole- 
cule in these vascular lesions. MAb provides a 
positive control group for ICAM-1 blockade in the 
immediate postoperative period, but because of its 
rapid clearance, a single perioperative dose would 
not be expected to influence vents resulting from a 
late up-regulation in ICAM-1. A single ex vivo 
treatment with AS ODN, on the other hand, was 
found to be increasingly effective over the time 
period analyzed. For example, when the efficacy of 
ICAM-1 blockade by AS ODN was assessed in our 
studies, a difference between transfected and con- 
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trol groups was more clearly demonstrated in allo- 
grafts at day 3 than day 1. 
This difference in pharmacokinetics of AS and 
MAb was further illustrated by their divergent bio- 
logic effects. Because of the central role that 
ICAM-1 plays on neutrophil diapedesis and toxicity 
during reperfusion, optimized blockade of early, 
preexisting ICAM-1 by means of MAb prevented 
reperfusion injury more effectively than AS ODN. 
More surprising were the results of the CGVD 
studies. Using the same PVG to ACI model, previ- 
ous studies have shown that the up-regulation of 
ICAM-l-mediated reperfusion injury resulted in 
worsened eventual CGVD. 16 However, despite its 
optimal effectiveness atreversing this initial nonspe- 
cific injury, ICAM-1 MAb was much less effective 
than AS ODN at reducing CGVD. The ICAM-I 
MAb used in these studies (1A29), because it is an 
Igl isotype MAb, potentially triggers recipient ef- 
fector mechanisms after interaction with its endo- 
thelial target (i.e., ICAM-1). It has been proposed 
that initiation of these effector mechanisms may 
inadvertently "activate" the endothelium and pro- 
mote early 17 or late is vascular injury. By targeting 
LFA-1, a ligand of ICAM-1 expressed on leukocytes 
and not endothelium, the WT.I MAb provides a 
positive control for the blockade of ICAM-1/LFA- 
l -mediated reperfusion injury without these theo- 
retical concerns of vascular injury. However, the 
reduction of reperfusion injury with LFA-1 MAb 
also failed to prevent CGVD. These results suggest 
that thc anti-CGVD mechanism of donor graft AS 
ICAM-10DN treatment is not fully explained by an 
initial reduction in reperfusion injury-mediated im- 
munogenicity and vascular injury. Further studies 
are needed to determine whether transfection leads 
to long-term reduction of perivascular ICAM-I by 
the persistence ofAS ODN or whether some change 
in allograft biology is triggered that provides a 
resistance to CGVD. 
Nonsequence-specific effects of ODN transfection 
on gene expression have been well documented, 
adding complexity to hasty conclusions regarding 
biologic effects. The aptamer effect 19 and direct 
antiproliferative and cytokine-inducing actions of 
certain ODN sequences 2° produce unpredictable, 
non-AS-related influences on biologic end points. In 
our studies, a true AS mechanism was supported by 
the lack of effect of (1) control RAS ODN on either 
target ICAM-I protein expression or CGVD, (2) AS 
ICAM-10DN on the expression of other gene 
products potentially important for CGVD (e.g., 
MHC class I and if), or (3) AS ODN treatment 
without pressure (vector control group) on CGVD. 
Indeed, ex vivo hyperbaric delivery of AS ODN to 
donor cardiac grafts resulted in a 48% transfection 
rate. Standard viral and lipid vectors have consis- 
tently shown transfection efficiency of less than 10% 
of total cells. 21' 22 Prolonged allograft survival has 
been accomplished with the use of these more 
technically difficult vectors by local overexpression 
of factors such as T-cell growth factor-/3 or inter- 
leukin-10. 21-23 However, AS ODN blocks target 
mRNA translation only in successfully transfected 
cells. Immunosuppression by means of this strategy 
obviously depends on transfection efficiency at levels 
much closer to that described by the hyperbaric 
vector. 
In conclusion, these studies document he sole 
use of pressure as a highly efficient vector for ODN 
delivery with documented efficacy of ICAM-1 block- 
ade. Compared with ICAM-1 MAb, AS ODN was 
less effective at preventing the manifestations of 
reperfusion injury, especially at early time points, a 
comparison which was consistent the pharmacoki- 
netics of these agents. Less well explained was their 
inverse effects on CGVD with ICAM-1 blockade 
with AS ODN but not perioperative MAb providing 
a significant preventive ffect on the development of
vascular lesions. Although further investigation re- 
garding the mechanism of AS ODN effect in this 
model is warranted, these studies support ongoing 
investigations in this laboratory using the more 
clinically relevant nonhuman primate transplanta- 
tion model. We think that this highly targeted 
alteration of donor organ immunogenicity may have 
an important future role in immunosuppressive 
strategies in clinical transplantation. 
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